Silver Spring, Maryland, USA, August 8, 2026
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically engineered oncolytic viral immunotherapy, for the treatment of adult patients with unresectable advanced cutaneous melanoma whose disease has progressed following anti-PD-1 immunotherapy. Approved for use in combination with nivolumab, the therapy introduces a new treatment option for patients with treatment-resistant melanoma, a population with limited therapeutic alternatives and poor clinical outcomes. The approval is supported by clinical trial data demonstrating durable anti-tumor responses in patients who had exhausted standard immunotherapy options. As the first approval of its kind for this difficult-to-treat patient group, Tudriqev represents an important advancement in cancer immunotherapy, utilizing a genetically modified virus to directly destroy tumor cells while stimulating the body’s immune system to recognize and attack cancer. The decision reflects the FDA’s continued commitment to accelerating access to innovative therapies for serious diseases with significant unmet medical need through its accelerated approval pathway.
Engineered Viral Therapy Targets PD-1 Resistant Melanoma
Tudriqev is based on a genetically modified herpes simplex virus type 1 (HSV-1) that has been engineered to selectively infect and destroy melanoma cells while activating anti-tumor immune responses. Once injected directly into tumors, the virus replicates inside cancer cells, causing them to rupture and release tumor-associated antigens that stimulate immune recognition. When administered together with nivolumab, a PD-1 immune checkpoint inhibitor, the treatment is designed to restore immune activity in patients whose tumors have developed resistance to previous anti-PD-1 therapies. The treatment regimen consists of intratumoral injections every two weeks for eight consecutive doses, with nivolumab administered intravenously beginning during the third week of therapy. By combining oncolytic viral therapy with checkpoint inhibition, the approach aims to improve immune-mediated destruction of advanced melanoma that no longer responds to conventional immunotherapy, offering a novel therapeutic strategy for a patient population facing limited treatment options.
Clinical Trial Demonstrates Durable Treatment Responses
The FDA approval was supported by results from an open-label, multiregional, single-arm clinical trial involving 140 adult patients with Stage IIIB, IIIC, or IV unresectable advanced melanoma whose disease progressed despite prior anti-PD-1 therapy. Among the 91 evaluable patients, investigators reported an objective response rate of 24%, with responding patients experiencing a median duration of response of 14.1 months, demonstrating clinically meaningful and durable anti-tumor activity. The study included patients who had received at least eight consecutive weeks of prior PD-1 inhibitor therapy, representing a particularly challenging treatment population. The most frequently reported adverse events included fatigue, fever, chills, infections, nausea, diarrhea, injection-site reactions, headache, musculoskeletal pain, rash, and influenza-like symptoms. Important safety considerations include the potential transmission or reactivation of herpes simplex virus infection, as well as injection-related complications, requiring careful patient monitoring throughout treatment.
Advertisement
Accelerated Approval Expands Melanoma Treatment Options
The approval of Tudriqev marks a significant advancement in the evolving field of cancer immunotherapy and reinforces the growing role of engineered viral therapies in oncology. The application received both Breakthrough Therapy Designation and Priority Review, reflecting the therapy’s potential to address a critical unmet medical need. Because the approval was granted under the FDA’s accelerated approval pathway, Replimune, Inc. must conduct additional post-marketing confirmatory clinical trials to verify and further demonstrate long-term clinical benefit. Continued regulatory approval will depend upon successful confirmation of these outcomes. As resistance to immune checkpoint inhibitors remains a major challenge in advanced melanoma treatment, the availability of Tudriqev provides oncologists with an innovative new therapeutic option capable of enhancing anti-tumor immunity through a unique dual mechanism. The approval highlights continued progress in viral immunotherapy, precision oncology, and next-generation cancer treatments, offering renewed hope for patients with advanced melanoma who previously had few effective treatment alternatives.
Source: FDA press release
